At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Nov 10, 2026 at 16:52 ET
Three Edwards Lifesciences insiders, including the CEO and a CVP, sold a total of $6.05M in open-market sales under 10b5-1 plans. The sales follow a strong Q3 earnings beat and raised guidance reported six days earlier. The dollar value is modest relative to the company's market cap, and the 10b5-1 plans indicate pre-arranged trading, reducing the signal.
- CEO Bernard Zovighian sold 23,100 shares (total $2.38M) under a 10b5-1 plan on Nov 9, 2026
- CVP Donald Bobo sold 48,900 shares ($5.04M) under a 10b5-1 plan on Nov 9, 2026
- CVP Daniel Lippis sold 619 shares ($65K) under a 10b5-1 plan on Nov 10, 2026
- Total open-market sales: $6.05M, all under 10b5-1 plans
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access